Clinical · Molecular biology
Meningioma methylation profiling as a complement to WHO grading: a single-center experience
Summary
This retrospective study assessed the clinical relevance of methylation profiling for meningioma risk stratification in 106 patients. Results indicated that methylation profiling, performed using the MethylationEPIC v1.0 chip, was a significantly superior predictor of tumor progression (r = -0.4, p < 0.001) compared to WHO 2021 grading. Although methylation profiling demonstrated enhanced predictive accuracy, particularly for identifying malignant meningiomas, its immediate clinical utility is constrained by a high rate of unclassified tumors (29%) and a delayed turnaround time for results (median 23 days), which is incompatible with prompt postoperative decision-making. The authors conclude that methylation profiling serves as a valuable complementary tool but cannot currently replace established histopathological assessment.
Critical appraisal
Clinical. This retrospective cohort study highlights the potential of methylation profiling as a prognostic biomarker superior to WHO grading for meningioma progression. Methylation profiling was significantly associated with tumor progression (r = -0.4, p < 0.001), unlike WHO grade (r = 0.17, p = 0.084). This finding would justify prospective Phase II/III clinical trials to validate its role in risk stratification and adapting surveillance or adjuvant treatment strategies. However, the 23-day turnaround time for results and the 29% rate of unclassified tumors currently limit its immediate impact on postoperative clinical decisions. For practice to change, a significant reduction in turnaround time and an improved classification rate would be necessary, which could take 3 to 5 years.
Molecular biology. The primary discovery is the superior predictive power of methylation profiling as a biomarker for meningioma progression. The technology employed is the MethylationEPIC v1.0 (850k) chip, a well-established epigenetic platform. Methylation profiling demonstrated superior analytical validity in terms of predictive capability compared to histopathological grading. Samples are derived from tumor resections, likely formalin-fixed paraffin-embedded (FFPE) tissue, which is standard in neuropathology. For clinical validation, the process would need optimization to reduce analysis time and improve classification algorithms to decrease the rate of unclassified tumors. Once validated, this test could be integrated into molecular diagnostic panels for meningioma patients to better guide surveillance and treatment decisions.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology